Key facts
- This page summarizes Mary L. Schapiro's Form 4 filing for CVS HEALTH Corp (CVS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 25 Nov 2024, 17:53.
Mary L. Schapiro - 21 Nov 2024 Form 4 Insider Report for CVS HEALTH Corp (CVS)
- Reporting relationship
- Director
- Issuer ticker
- CVS
- Reported as of
- 21 Nov 2024
- Net transaction value
- +$167,500
- SEC form
- 4
- Accepted by SEC
- 25 Nov 2024, 17:53:55 UTC
- Prior SEC filing
- 03 Jun 2024
- Next SEC filing
- 03 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mary L. Schapiro
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mary L. Schapiro filed Form 4 for CVS HEALTH Corp (CVS) on 25 Nov 2024.
Change
- Previous filing in this sequence was filed on 03 Jun 2024.
- Current net transaction value: +$167,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CVS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 11,844
- Date
- 21 Nov 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CVS
transaction
Derivative
Deferred Stock Units
Award
- Transaction value
- $167,500
- Shares
- +2,933
- Change %
- +14%
- Price
- $57.10
- Shares after
- 24,437
- Date
- 21 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,933
- Exercise price
- $0.000000
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.
Footnote F2
Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person.